MicroPort Scientific (0853) AI Stock Analysis

• Market Cap: HK$19.40B
• Dividend Yield: N/A
• Average Volume (3M): 25.37M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.89
• Revenue Growth: -1.04%
• EPS Growth: 60.66%
• Country: HK
• Employees: 6,347
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.22
• Shares Outstanding: 1,912,947,600
• 10 Day Avg. Volume: 21,967,342
• 30 Day Avg. Volume: 25,373,873
• PEG Ratio: 0.12
• Price to Book (P/B): 2.40
• Price to Sales (P/S): 1.40
• P/FCF Ratio: -9.16
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$15.02
• Price Target Upside: 37.78% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: HK$11.00 ▲(0.92% Upside)

The overall stock score is primarily impacted by significant financial challenges, including persistent losses and liquidity issues. Technical analysis provides a slightly more balanced view, but the negative valuation metrics further weigh down the score. The absence of earnings call insights and corporate events means these factors do not influence the score.

Positive Factors

R&D Focus

A strong focus on R&D can lead to innovative products, improving competitive positioning and long-term growth potential in the medical devices sector.

Global Partnerships

Partnerships expand market reach and product development, enhancing revenue streams and competitive advantage in the global market.

Revenue Streams

Diverse revenue streams from sales, partnerships, and licensing provide stability and potential for sustainable growth despite market fluctuations.

Negative Factors

High Leverage

High leverage indicates financial instability, increasing risk and limiting flexibility for future investments or downturns.

Negative Cash Flow

Consistent negative cash flow from operations suggests reliance on external financing, posing risks to financial health and sustainability.

Profitability Challenges

Persistent operational inefficiencies and cost management issues hinder profitability, impacting long-term financial stability and growth.

MicroPort Scientific Business Overview & Revenue Model

Company Description

MicroPort Scientific Corporation, an investment holding company, manufactures, and markets, and distributes medical devices in the People's Republic of China, North America, Europe, other Asian countries, South America, and internationally. The company's Cardiovascular Devices segment offers products and services for the treatment of coronary artery-related diseases; coronary stents and related delivery systems; and balloon catheters and accessories. Its Orthopedics Devices segment provides reconstructive joints, spine and trauma, and other professional implants and instruments. The company's Cardiac Rhythm Management Business segment offers defibrillators, cardiac resynchronization therapy devices, and pacemakers for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Its Endovascular and Peripheral Vascular Devices segment provides products and services for the interventional treatment of thoracic and abdominal aortic aneurysm, peripheral vascular diseases, aortic dissection, and other endovascular related diseases. The company's Neurovascular Devices segment offers neurovascular therapeutic and access devices for neurovascular diseases. Its Heart Valve Business segment provides VitaFlow Transcatheter aortic valve and delivery system, VitaFlow Liberty Transcatheter aortic valve implantation and retrievable delivery systems, Alwide Plus Balloon Catheter, various transcatheter aortic valve implantation, transcatheter mitral valve, transcatheter tricuspid valve, and surgical valve products. The company's Surgical Robot Business segment designs, develops, and commercializes surgical robots comprising robot ontology, control algorithm, electrical engineering, image-based navigation, and precision imaging. Its Surgical Devices segment researches and develops, manufactures, and sells surgical devices. MicroPort Scientific Corporation was founded in 1998 and is headquartered in Shanghai, the People's Republic of China.

How the Company Makes Money

MicroPort Scientific generates revenue through the sale of its medical devices across various sectors, including cardiovascular, orthopedics, and neurosurgery. The company has established key revenue streams from direct sales to hospitals and healthcare providers, as well as partnerships with distributors and healthcare organizations that facilitate the distribution of its products. Significant partnerships with international medical institutions and collaborations with research entities also contribute to its earnings, as they enhance product development and market reach. Additionally, the company benefits from ongoing revenue through product maintenance and support services, as well as potential royalties from licensing agreements related to its innovative technologies.

MicroPort Scientific Financial Statement Overview

Summary

MicroPort Scientific faces considerable financial challenges characterized by persistent losses, high leverage, and cash flow issues. Despite revenue growth, the company's profitability and liquidity remain weak, necessitating strategic improvements in cost management and operational efficiency to stabilize its financial position.

Income Statement

The income statement shows significant challenges in profitability, with a negative net income and EBIT over the past three years. Although there has been a revenue growth trend from 2020 to 2024, the company has consistently reported negative EBIT and net profit margins, indicating persistent operational inefficiencies and cost management issues.

Balance Sheet

The balance sheet highlights a concerning increase in total debt over the years, contributing to a high debt-to-equity ratio. Stockholders' equity has decreased significantly, reflecting financial instability. The equity ratio has also declined, indicating a heavier reliance on debt financing. These factors suggest potential solvency risks.

Cash Flow

The cash flow statement reveals negative operating cash flows, which paired with consistent negative free cash flows, indicates liquidity challenges. The company has been unable to generate positive cash flows from operations, relying heavily on financing activities to sustain operations, which poses a risk to financial health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.02B	1.03B	950.73M	840.83M	778.64M	648.73M
Gross Profit	552.09M	574.09M	532.10M	501.77M	491.77M	436.03M
EBITDA	-13.83M	-45.30M	-382.54M	-430.26M	-256.35M	-106.87M
Net Income	-163.81M	-214.04M	-477.63M	-436.51M	-276.48M	-191.25M
Balance Sheet
Total Assets	3.77B	3.63B	3.93B	3.99B	4.38B	2.47B
Cash, Cash Equivalents and Short-Term Investments	957.62M	974.48M	1.06B	1.24B	1.75B	1.00B
Total Debt	1.76B	1.69B	1.70B	1.47B	1.24B	296.31M
Total Liabilities	2.59B	2.49B	2.53B	2.20B	2.16B	1.08B
Stockholders Equity	623.12M	603.47M	757.82M	1.14B	1.49B	1.13B
Cash Flow
Free Cash Flow	-83.89M	-158.10M	-430.99M	-600.58M	-505.45M	-143.58M
Operating Cash Flow	-27.76M	-49.67M	-231.87M	-343.30M	-257.53M	-23.20M
Investing Cash Flow	16.02M	-149.73M	-376.81M	-412.75M	-655.74M	-148.13M
Financing Cash Flow	37.18M	-97.92M	434.90M	273.00M	1.66B	846.89M

MicroPort Scientific Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 10.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0853, the sentiment is Neutral. The current price of 10.9 is above the 20-day moving average (MA) of 10.73, below the 50-day MA of 11.49, and above the 200-day MA of 10.22, indicating a neutral trend. The MACD of -0.30 indicates Negative momentum. The RSI at 50.25 is Neutral, neither overbought nor oversold. The STOCH value of 36.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0853.

MicroPort Scientific Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1789	69 Neutral	HK$6.10B	19.06	11.24%	1.32%	25.18%	55.79%
2172	58 Neutral	HK$6.06B	27.39	11.79%	1.54%	-5.18%	-9.69%
1302	57 Neutral	HK$6.48B	88.20	1.98%	―	3.42%	-70.82%
1858	55 Neutral	HK$9.11B	21.27	8.69%	1.85%	14.56%	61.60%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
0853	46 Neutral	HK$19.40B	-15.77	-24.77%	―	-1.04%	60.66%
2252	38 Underperform	HK$20.73B	-39.32	-117.51%	―	112.97%	37.70%

MicroPort Scientific Corporate Events

MicroPort Scientific Reports Mixed Financial Results for Endovastec

MicroPort Scientific has released the unaudited financial results for its subsidiary, Shanghai MicroPort Endovascular MedTech (Endovastec), for the nine months ending September 30, 2025. The results show a modest revenue increase of 4.66% compared to the same period in 2024, but a significant decline in profit by 21.80%. Despite the profit drop, Endovastec’s total assets grew by 10.27%, indicating a strong asset base. Investors are advised to exercise caution as these figures are unaudited and do not represent the full scope of the Group’s operations.

MicroPort Scientific Adopts New Governance Framework

MicroPort Scientific Corporation announced that a special resolution to adopt the fifth amended and restated memorandum and articles of association was unanimously approved at the extraordinary general meeting held on October 22, 2025. This change reflects the company’s commitment to updating its governance framework, potentially impacting its operational efficiency and stakeholder engagement.

MicroPort Scientific Announces Board Restructuring

MicroPort Scientific Corporation announced changes to its board of directors and board committees, effective from September 30, 2025. The company has accepted the resignations of Mr. Hiroshi Shirafuji and Mr. Norihiro Ashida as non-executive directors, who will continue to serve as advisors. Dr. Feng Gu has been appointed as a new non-executive director, bringing extensive experience in financial management and corporate governance. These changes are expected to enhance the company’s strategic direction and governance, potentially impacting its market positioning and stakeholder relations positively.

MicroPort Scientific Announces Board Composition and Committee Roles

MicroPort Scientific Corporation has announced the composition of its board of directors and the roles within its established committees. This announcement provides clarity on the leadership structure, which is crucial for stakeholders to understand the governance and strategic direction of the company.

MicroPort Scientific Announces EGM to Revise Governance Documents

MicroPort Scientific Corporation has announced an extraordinary general meeting to be held on October 22, 2025, in Shanghai, China. The meeting aims to approve and adopt the fifth amended and restated memorandum of association and articles of association, which will replace the existing ones. This move is expected to streamline the company’s governance structure and enhance operational efficiency, potentially impacting its market positioning and stakeholder relations.

MicroPort Scientific Announces Strategic Merger to Enhance Cardiac Solutions

MicroPort Scientific has announced a merger agreement involving its subsidiary, MicroPort CardioFlow, and CRM Cayman, which will become an indirect wholly-owned subsidiary of MicroPort CardioFlow. This strategic restructuring aims to enhance MicroPort CardioFlow’s product offerings and global presence in the heart disease market. The merger is expected to improve the financial position of CRM Cayman, optimize the Group’s financing structure, and reduce overall finance costs, benefiting stakeholders by strengthening the company’s market positioning and operational efficiency.